Objectives: To study the association between angiopoietin 2 (Ang2) concentrations in tracheal aspirates (TAs) and adverse outcome (bronchopulmonary dysplasia (BPD)/death) in ventilated premature infants (VPIs) and modulation of Ang2 concentrations with dexamethasone (Dex) use.
Introduction
One of the important causes of morbidity and mortality in premature infants is bronchopulmonary dysplasia (BPD), which in the United States, is the leading cause of chronic lung disease in babies and the third leading cause in children. Despite the advent of antenatal steroids and surfactant replacement therapy for the management of respiratory distress syndrome, the incidence of BPD has not changed significantly in the last decade. 1 BPD may lead to significant pulmonary sequelae, including reactive airway disease and asthma during childhood and adolescence. 2 Thus, a disease initiated so early in life has consequences well into adulthood. 3 In the context of the increased rate of prematurity, 4 the burden of BPD is expected to increase. Therefore, an ability to identify a population that is predisposed to BPD would be the important first step in targeting specific therapy to ameliorate the same. Ideally, such a marker would also be biologically relevant in the pathogenesis of BPD.
The pathogenesis of BPD is complex and involves numerous factors. 2, 5, 6 Sepsis in utero, in addition to ventilator-induced injury and hyperoxia, initiates an inflammatory cascade, which acts on the immature lungs. 2 Inflammation interferes with the normal development of airways and alveoli, and abnormal healing in the premature infant further exacerbates lung damage, resulting in BPD. 2 While the role of angiopoietin 2 (Ang2) in regulating angiogenesis and vascular integrity has been well recognized, 7, 8 recent reports have implicated an important role in inflammation. [9] [10] [11] [12] Ang2 expression is increased dramatically at the sites of endothelial activation and is induced by various cytokines. 13 The release of Ang2 resulted in rapid destabilization of the endothelium and triggered an inflammatory response. [13] [14] [15] A recent study has highlighted Ang2 as having a critical role in animal models of hyperoxia-induced lung injury and inflammation.
12 Ang2 caused increased inflammation and cell death in the lung on exposure to hyperoxia. 12 In addition, it was reported that tracheal aspirate (TA) concentrations of Ang2 were increased in a small number of babies with respiratory distress syndrome who went on to have adverse outcome (BPD/death).
Hence, we hypothesized that Ang2 has an important role in the pathogenesis of BPD. Our objective in the present study was to measure Ang2 in TA samples and its association with the development of BPD or death, in a large cohort of VPIs. In addition, we wanted to evaluate the effect of dexamethasone (Dex) use on Ang2 concentrations.
Methods

Study population
The study was conducted in a 39-bed, level III neonatal intensive care unit at Cooper University Hospital in Camden, NJ, between March 2003 and October 2006. The Institutional Review Committee approved the study, and all parents signed a written informed consent. Infants born before 32 weeks gestation and requiring mechanical ventilatory support were eligible for participation. Relevant clinical data, including the infant's demographics, clinical parameters and data on respiratory support, were collected from the patient's chart. BPD was defined as the need for supplemental oxygen at 36 weeks postmenstrual age (PMA).
Sample collection
Tracheal aspirate samples were collected on days 1, 3, 5 and 7 while the infants were mechanically ventilated. Additional TA samples were collected before and 48 to 72 h after the starting steroid course. The decision to treat an infant with steroids was left to the discretion of the attending neonatologist based on the current American Academy of Pediatrics guidelines. Infants received a 9-day weaning course of Dex (0.3 mg per kg per day for 3 days, 0.2 mg per kg per day for 3 days and 0.1 mg per kg per day for 3 days). TA samples were obtained by instilling 0.5 ml of normal saline into the infant's endotracheal tube and suctioning the residue with a 5F suction catheter after two or three ventilator breaths. The suction catheter was passed to a standardized length of 0.5 to 1 cm beyond the tip of the endotracheal tube. This method of collection is used widely in neonates to collect TA samples, [16] [17] [18] and it is well tolerated by even the most critically ill neonates. The procedure was repeated three times and replicates were pooled. The suction catheter was flushed with 0.5 ml of normal saline after each suctioning episode to collect the residual sample in the catheter. The samples were immediately transported to the laboratory on ice and processed within half-an-hour in the laboratory. The samples were centrifuged at 4 1C for 10 min at 300 g. The supernatant was collected, divided into aliquots and stored at À70 1C for future use.
Ang2 assay
The concentration of Ang2 was measured using commercially available ELISA kit (R&D Systems Inc., Minneapolis, MN, USA) according to manufacturer's instruction. The minimum detectable amount (sensitivity) of this assay ranged from 1.2 to 21.3 pg ml À1 , with a mean value of 8.3 pg ml À1 . There was no cross-reactivity with Ang1, Tie-2 or vascular endothelial growth factor (VEGF).
Protein assay
Total protein concentration was measured in each TA sample by the Bradford assay (Bio-Rad, Richmond, CA, USA) to correct for dilution during the lavage procedure. The concentration of Ang2 was expressed in pg per mg of protein.
Statistical analyses
Statistics were performed using SigmaStat 3.1 for Windows statistical package (Systat Software Inc., Point Richmond, CA, USA). We did sample size calculations. The minimum number of cases that would allow a difference in the mean values of the Ang2 concentrations to be approximately equal to the s.d. of the group, for a power of 0.8 at an a ¼ 0.05, was 12. Comparisons between groups were done using Student's t-test, Mann-Whitney U-test, Wilcoxon signed rank-test for continuous data and w 2 -or Fisher's exact test for categorical data. Stepwise logistic regression was done with variables entered in the model if P<0.05 and excluded if P>0.1. Receiver-operating characteristic curve analysis was performed using MedCalc (Broekstraat, Belgium) statistical software. The difference was considered significant at Pp0.05.
Results
A total of 151 TA samples were collected from 60 VPIs (mean ± s.d., birth weight (BW) 780 ± 183 g, gestational age 25.6±1.7 weeks) during the first week of life. Additional 54 TA samples were collected from 26 infants who received 27 courses of steroids. During the first 7 days, Ang2 was detectable in 137 (90.7%) of the 151 samples. The median Ang2 concentration of all aspirates was 110 pg ml À1 (range 0 to 1041 pg ml À1 ).
BPD, mortality and Ang2
Twelve infants had no BPD, 32 infants developed BPD and 16 infants died before 36 weeks PMA. Clinical characteristics of the three groups are summarized in Table 1 . BW was higher in infants with no BPD compared with infants who developed BPD or died. The duration of mechanical ventilation, oxygen therapy and hospitalization was also higher in infants with BPD. However, there were no significant differences in gestational age and other demographics in infants who developed BPD and those who did not. Similarly, there was no significant difference in the number of samples collected from infants with no BPD (total 28, average 2.3 samples per infant), BPD (total 85, average 2.6) and infants who died (total 38, average 2.4). The mean Ang2 concentration was lower in infants with no BPD (median, 25th and 75th percentile) (157, 16 and 218 pg mg À1 ) compared with those who developed BPD (234, 138 and 338 pg mg À1 , P ¼ 0.03, Mann-Whitney U-test; Figure 1a ) and when compared to those who developed BPD or died (234, 157 and 347 pg mg
À1
, P ¼ 0.017, Mann-Whitney U-test; Figure 1b ). This held true even when Ang2 concentrations were not corrected for dilution and expressed in pg ml À1 (Figures  2a and b) .
The concentration of Ang2 was lower at all time points (days 1, 3, 5 and 7) in infants with no BPD compared with those who developed BPD, but it reached significance only on day 1 (no BPD 209, 51 and 295 pg mg À1 versus BPD 363, 225 and 892 pg mg À1 , P ¼ 0.04) and day 7 (no BPD 64, 6 and 106 pg mg À1 versus BPD 204, 95 and 350 pg mg À1 , P ¼ 0.04; Figure 3a ). The concentration of Ang2 was lower at all time points (days 1, 3, 5 and 7) in infants with no BPD compared to BPD/death, but it reached significance only on day 1 (no BPD 209, 51 and 295 pg mg À1 versus BPD/death 368, 213 and 657 pg mg À1 , P ¼ 0.03) and day 7 (no BPD 64, 6 and 106 pg mg À1 versus BPD/ death 254, 96 and 348 pg mg À1 , P ¼ 0.01; Figure 3b ). In a logistic regression model, Ang2 concentrations and BW were found to be independent predictors of outcome (Ang2 P ¼ 0.02, BW P ¼ 0.01). Together, these two variables were highly predictive of outcome (P ¼ 0.0001), correctly classifying 85% of cases.
The cutoff Ang2 value with the highest accuracy was found to be 295 pg mg À1 , with a sensitivity and specificity of 60 and 80%, and a positive and a negative predictive values of 87 and 47%, respectively, on day 1. On day 7, the Ang2 concentration of 141 pg mg À1 had a sensitivity and specificity of 67 and 100%, and positive and negative predictive values of 100 and 50%, respectively.
Dex and Ang2
Twenty-six premature neonates (mean ± s.d.: BW 719 ± 136 g, gestational age 25.1±1.3 weeks) received 27 courses of Dex. The median age of starting steroids was 24 days (range 13 to 60 days). The mean concentration of Ang2 before starting Dex was (202, 137 and 278 pg mg
À1
) and significantly decreased to (144, 0 and 224 pg mg À1 ) after therapy with Dex (P ¼ 0.007, Wilcoxon signedrank-test; Figure 4a ). This held true even when Ang2 concentrations were not corrected for dilution and expressed in pg ml À1 (Figure 4b ).
Discussion
This study shows that TA Ang2 concentrations are significantly increased in babies, in the first week of life, who have an adverse outcome (BPD and/or death). Measurement of inflammatory cytokines in TAs has been utilized by a multitude of investigators to identify a population of VPIs developing BPD, with a vast array of markers being proposed. Infants who developed BPD had significantly increased concentrations of soluble intracellular adhesion molecule-1, [19] [20] [21] tumor necrosis factor-a, 22 transforming growth factor-b-1, 30 fibroblast growth factor-2 31 and endothelin-1. 24 Others have been unable to confirm IL-1b, IL-6, macrophage inflammatory protein-1-a, -b and endothelin-1 31 in the TA as markers for BPD. 29, 32 Infants with subsequent development of BPD had lower hepatocyte growth factor, 33 keratinocyte growth factor 34 and parathyroid hormone-related protein concentrations in TAs. 35 Babies developing BPD had lower 36 or no association 31 with VEGF in TAs compared with those surviving without BPD.
It is important to remember that the source of these biomolecules can be from a variety of lung cells and are contextas well as concentration dependent, and measurements in one spatial or temporal niche may not be extrapolatable to another niche. While one study has shown that TA specimens may be the suitable substitute for bronchoalveolar lavage samples in preterm infants, 37 there has been some controversy regarding whether the measurements of these markers in the TA need to be 'normalized' for them to be valid. While some have advocated the use of total protein, 12, 38 secretory component of immunoglobulin A 29,39 -43 and serum urea 17, 30 for the same, others have espoused that no 'normalization' is required. 31,44 -46 This study has reported Ang2 values normalized to total protein to correct for dilution. However, even when the data were expressed without correcting for dilution, Ang2 concentrations remained significantly elevated in babies who went on to develop BPD and/or died (Figures 2a and b) .
The majority of studies have been conducted in a small number of babies, with the TAs collected at a variable number of time points, measurements done with or without 'normalization' and with variable definitions of BPD (oxygen requirement for 28 days or at 36 weeks PMA). Only some of cytokines (IL-1b, IL-6, IL-8, keratinocyte growth factor, monocyte chemoattractant protein-1 and VEGF) have been implicated in lung injury/inflammation in animal models or in vitro studies. 47 Consistent TA concentrations have been replicated in different study populations in only some instances. These include soluble intracellular adhesion molecule-1, IL-1b, IL-6 and IL-8. 17, 19, 20, [22] [23] [24] [25] [26] 28 In contrast, conflicting results have been reported for VEGF 31, 36 and endothelin-1 24, 31 TA values in VPIs at risk of developing BPD. Thus, it is difficult to discern the clinical utility of such measurements of a majority of cytokines unless it has been consistently replicated in disparate populations, using standard definitions and techniques.
The strengths of this study include the facts that the present study population is different from that originally reported, 12 a large cohort of VPIs have been included, multiple samples were obtained at clinically relevant time points and BPD was defined at 36 weeks PMA. Thus, this study shows the translational relevance of Ang2, in the appropriate clinical setting. Data from diverse populations in other neonatal intensive care units would be necessary for further confirmation. It is important to mention, however, that the biological relevance of Ang2 in the area of lung injury/ inflammation has been proven in animal models and in vitro studies. 12 Interestingly, it was noted that Dex therapy was associated with a significant decrease in Ang2 concentrations. This remained significant even when Ang2 concentrations were expressed without correcting for dilution (Figure 4b) . We do not have data for VPIs who did not receive steroids and were still intubated at comparable Figure 4 The concentration of angiopoietin 2 (Ang2) (corrected for dilution) before and after steroid therapy (n ¼ 27). The concentration of Ang2 significantly decreased after treatment with dexamethasone (P ¼ 0.007) (a). Similar results were obtained with Ang2 concentrations that were uncorrected for dilution (P ¼ 0.01) (b). Box plot: the boundary of the box indicates the 25th and 75th percentiles, the line within the box marks the median value and the error bars indicate the 5th and 95th percentiles.
postnatal ages. Interestingly, Ang2 was suppressed by steroids in infants with or without BPD, that is, there was no differential effect of steroid on Ang2 depending on BPD status. However, our sample size is small, with only five infants with no BPD in this cohort. A reduction in TA hepatocyte growth factor concentrations has been reported with the use of postnatal Dex in VPIs at risk for developing BPD, 33 although interestingly, the same group of investigators has reported lower TA hepatocyte growth factor concentrations in babies with BPD. 42 Bronchoalveolar lavage concentrations of VEGF were increased on day 7 in VPIs receiving Dex, compared with controls. 48 Since Dex is well known to decrease inflammation, 49, 50 and increased Ang2 enhances inflammation/injury in the lung, 12 the association of decreased Ang2 concentrations after administration of Dex raises the intriguing possibility that antiAng2 therapies may have some potential beneficial effects. Further research is needed to definitively answer these questions. In summary, this study has noted significantly increased TA Ang2 concentrations in VPIs who go on to develop BPD and/or die. In addition, Dex therapy was associated with a significant reduction in TA Ang2 values.
